Opinion: GMOs Are Not “Frankenfoods”

It behooves the scientific community to reflect on the public’s “Franken-” characterization of genetically modified foods.

Written byDov Greenbaum and Mark Gerstein
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

FLICKR, CHRIS DRUMMTwo centuries ago, during the dreary and bleak Mount Tambora volcanic winter of 1816, Mary Shelly began writing what would become her magnum opus, Frankenstein. No other work of fiction can claim to have such a lasting impact in articulating the public’s visceral fears of scientific and technological innovation. Indeed, the pejorative prefix Franken- has taken on a life of its own, attaching itself to many instances where innovation has outpaced our comfort zone, most prominently in the area genetically modified organisms (GMO)—also known as “Frankenfoods.”

More often than not, however, this anti-GMO characterization does not echo scientific reality. GMO foodstuffs have been around for decades and are grown in both developed and developing countries around the world by millions of farmers on millions of acres of arable land. A number of genetically modified crops are currently commercially farmed in the U.S., including alfalfa, canola, corn, cotton, papaya, squash, and sugar beets. Typically these modified crops are engineered to have added benefits such as resistance and tolerance to many environmental stresses—herbicides, insects, drought, salinity, and lack of soil nutrients—or added enzymes or increased yields and nutrients. Many of these benefits provide solutions to real and urgent problems in our food supply, and the National Academies of Science have repeatedly found that ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies